A5058603542- RNA Interference and Gene Delivery
- 3D Printing in Biomedical Research
- Cell death mechanisms and regulation
- Microfluidic and Bio-sensing Technologies
- Peroxisome Proliferator-Activated Receptors
- Cancer Cells and Metastasis
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer therapeutics and mechanisms
- Bacteriophages and microbial interactions
- Neuroendocrine Tumor Research Advances
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- Protein Degradation and Inhibitors
Institute for Bioengineering of Catalonia
2021-2025
Universitat de Barcelona
2025
Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine
2025
Universitat Autònoma de Barcelona
2022
Abstract Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention in last decade as potential targeted cancer therapies. However, little is known about molecular determinants cell sensitivity to FASN inhibitors (FASNis), which a major roadblock their therapeutic application. Here, we find that pharmacological starvation endogenously produced FAs previously unrecognized metabolic stress heightens mitochondrial apoptotic priming and favors death induction by...
Abstract ALK (anaplastic lymphoma kinase) rearrangements represent the third most predominant driver oncogene in non-small cell lung cancer (NSCLC). Although inhibitors are tyrosine kinase (TKIs) with longest survival rates cancer, complex systemic clinical evaluation and apoptotic death evasion of drug-tolerant persister (DTP) cells may limit their therapeutic response. We found that dynamic BH3 profiling (DBP) presents an excellent predictive capacity to ALK-TKIs, would facilitate use a...
Abstract Treatment-naïve small cell lung cancer (SCLC) is typically susceptible to standard-of-care chemotherapy consisting of cisplatin and etoposide recently combined with PD-L1 inhibitors. Yet, in most cases, SCLC patients develop resistance first-line therapy alternative therapies are urgently required overcome this resistance. In study, we tested the efficacy dinaciclib, an FDA-orphan drug inhibitor cyclin-dependent kinase (CDK) 9, among other CDKs, SCLC. Furthermore, report on a newly...
Targeted agents have emerged as promising molecules for cancer treatment, but most of them fail to achieve complete tumor regression or attain durable remissions due adaptations. We used dynamic BH3 profiling identify targeted effectiveness and anti-apoptotic adaptations upon treatment in rhabdomyosarcoma. focused on studying the use mimetics specifically inhibit pro-survival BCL-2 family proteins, overwhelm resistance therapy prevent relapse. observed that MEK1/2 inhibitor trametinib...
Abstract One of the most promising approaches in drug delivery field is use naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles systems (DDSs). Among them, eukaryotic vaults show a future due to their structural features, vitro stability and non-immunogenicity. Recombinant are routinely produced insect cells purified through several ultracentrifugations, both tedious time-consuming...
Abstract Precision medicine is starting to incorporate functional assays evaluate anticancer agents on patient-isolated tissues or cells select for the most effective. Among these new technologies, dynamic BH3 profiling (DBP) has emerged and extensively been used predict treatment efficacy in different types of cancer. DBP uses synthetic peptides measure early apoptotic events (‘priming’) anticipate therapy-induced cell death leading tumor elimination. This predictive assay presents multiple...